

## **WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)**

### **Retrovir 100 mg capsules, hard<sup>1</sup>**

Zidovudine 100 mg Capsules, hard

Retrovir 100 mg capsules, hard, was submitted in 2001 by Glaxo Wellcome Operations, United Kingdom, to be considered for prequalification and subsequently accepted for the WHO list of prequalified products for treatment of HIV/AIDS on 29 May 2002.

Information on the site(s) involved in the manufacture of the product and the API is available at the products listing information <https://extranet.who.int/pqweb/medicine/2380>

The “Procedure for prequalification of pharmaceutical products<sup>2</sup>” defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQTm), is based on the approval by the United Kingdom “Medicines & Healthcare products Regulatory Agency” (MHRA, <http://www.mhra.gov.uk>) in line with the “Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities”<sup>3</sup>.

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Programme.

However, according to the SRA guideline WHO may request additional data when considered necessary for the safe use of the product in regions relevant for prequalified products and such information may be included in the WHOPAR as a separate piece of information. In order to safeguard product quality throughout its entire intended shelf-life in hot and very humid areas, stability studies under the conditions defined for Climatic Zones IVb have been requested from the Applicant<sup>4</sup>.

Based on the submitted stability data WHO PQTm considers the following storage condition appropriate for the product when distributed in regions with zone III, IVa and IVb climatic conditions, based on available stability information:

- Do not store above 30°C.
- Store in the original package to protect from light.
- The shelf-life at this storage condition is 60 months.

---

<sup>1</sup> Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority’s responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

<sup>2</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2)

<sup>3</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2)

<sup>4</sup> [https://extranet.who.int/pqweb/sites/default/files/documents/48\\_Stability\\_data\\_SRA\\_FPPs\\_March2016\\_newtempl.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/48_Stability_data_SRA_FPPs_March2016_newtempl.pdf)

This WHOPAR refers to the information available at the approving stringent regulatory authority's website resulting from the assessment of the quality, efficacy and safety as well as steps taken after approval.

<https://products.mhra.gov.uk/search/?search=Retrovir&page=1&doc=Par&rerouteType=0>

For details on the uses of this product, for relevant efficacy and safety information see the summary of product characteristics and the patient information leaflet as approved by MHRA <https://products.mhra.gov.uk/search/?search=Retrovir&page=1> PL 35728/0001

This WHOPAR for Retrovir is comprised of parts 2, 5 and 7.

Retrovir contains zidovudine. Its WHO recommended use is for the treatment of HIV/AIDS

The efficacy and safety profile zidovudine is well established based on the extensive clinical experience in the treatment of HIV infected patients.

**Summary of Prequalification Status for Retrovir 100 mg capsules, hard:**

	Initial Acceptance		Requalification	
	Date	Outcome	Date	Outcome
Status on PQ list	29 May 2002	listed	27 Nov 2017	listed
Dossier Evaluation	12 April 2002	MR	07 Nov 2017	requalified

PQ: prequalification

MR: meets requirements

The table represents the status of relevant completed activities only.